Precision Biosciences Inc. Insider Trading

DTIL

Cluster buy

3 insiders bought 30K of their own stock in 4 days.

Open-market purchases by executives and directors between Sep 25 and Sep 28. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market

−368K

6 buys · 8 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

3 / 4

executives and directors

Last open-market buy

Sep 2026

Sep 28, 2026

Get an email when DTIL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 28	Stanley Frankel Director	Bought	1,000	$6.00	6K	2.5%	Form 4
Sep 25	Melinda Brown Director	Bought	1,135	$6.27	7K	2.6%	Form 4
Sep 25	Geno J Germano Director	Bought	2,609	$6.28	16K	5.8%	Form 4
Feb 18	Michael Amoroso President and CEO	Sold10b5-1 plan	20,559	$3.84	79K	7.8%	Form 4
Feb 18	John Alexander Kelly Chief Financial Officer	Sold10b5-1 plan	8,149	$3.84	31K	6.1%	Form 4
Feb 18	Dario Scimeca General Counsel and Secretary	Sold10b5-1 plan	4,925	$3.84	19K	8.0%	Form 4
Feb 18	J. Jefferson Smith Chief Research Officer	Sold10b5-1 plan	4,925	$3.84	19K	3.7%	Form 4
Jan 22	Michael Amoroso President and CEO	Sold10b5-1 plan	34,799	$4.17	145K	15%	Form 4
Jan 21	Dario Scimeca General Counsel and Secretary	Sold10b5-1 plan	8,854	$4.03	36K	17%	Form 4
Jan 21	John Alexander Kelly Chief Financial Officer	Sold10b5-1 plan	15,213	$4.03	61K	13%	Form 4
Jan 21	J. Jefferson Smith Chief Research Officer	Sold10b5-1 plan	10,200	$4.03	41K	7.9%	Form 4
Dec 16, 2025	Geno J Germano Director	Bought	3,000	$4.72	14K	14%	Form 4
Dec 16, 2025	Stanley Frankel Director	Bought	2,700	$4.70	13K	16%	Form 4
Dec 15, 2025	Melinda Brown Director	Bought	1,381	$4.97	7K	6.3%	Form 4
Nov 3, 2025	John Alexander Kelly Chief Financial Officer	Sold10b5-1 plan	1,303	$6.49	8K	1.7%	Form 4
Nov 3, 2025	Dario Scimeca General Counsel and Secretary	Sold10b5-1 plan	665	$6.49	4K	2.3%	Form 4
Nov 3, 2025	Michael Amoroso President and CEO	Sold10b5-1 plan	3,409	$6.49	22K	2.9%	Form 4
Sep 26, 2025	Stanley Frankel Director	Bought	2,700	$4.97	13K	19%	Form 4
Sep 22, 2025	Melinda Brown Director	Bought	1,400	$4.89	7K	6.8%	Form 4
Jul 3, 2025	John Alexander Kelly Chief Financial Officer	Sold10b5-1 plan	14,827	$4.26	63K	17%	Form 4
Jun 25, 2025	Melinda Brown Director	Bought	1,682	$4.14	7K	8.9%	Form 4
Jun 25, 2025	Kevin Buehler Director	Bought	5,076	$4.16	21K	22%	Form 4
Mar 26, 2025	Melinda Brown Director	Bought	1,839	$4.75	9K	25%	Form 4
Mar 26, 2025	Kevin Buehler Director	Bought	4,523	$4.67	21K	52%	Form 4
Mar 25, 2025	Geno J Germano Director	Bought	3,250	$5.30	17K	42%	Form 4
Mar 24, 2025	Michael Amoroso President and CEO	Sold10b5-1 plan	964	$5.56	5K	0.9%	Form 4
Mar 4, 2025	Dario Scimeca General Counsel and Secretary	Sold10b5-1 plan	272	$4.91	1K	1.1%	Form 4
Mar 4, 2025	J. Jefferson Smith Chief Research Officer	Sold10b5-1 plan	154	$4.91	$756	0.2%	Form 4
Jan 22, 2025	Dario Scimeca General Counsel and Secretary	Sold10b5-1 plan	8,928	$4.79	43K	27%	Form 4
Jan 22, 2025	J. Jefferson Smith Chief Research Officer	Sold10b5-1 plan	10,287	$4.79	49K	9.7%	Form 4
Jan 21, 2025	Michael Amoroso President and CEO	Sold10b5-1 plan	36,838	$4.67	172K	26%	Form 4
Dec 30, 2024	Geno J Germano Director	Bought	3,605	$4.49	16K	86%	Form 4
Dec 27, 2024	Kevin Buehler Director	Bought	4,320	$4.88	21K	98%	Form 4
Dec 27, 2024	John Alexander Kelly Chief Financial Officer	Bought	2,113	$4.75	10K	5.5%	Form 4
Dec 26, 2024	Melinda Brown Director	Bought	3,016	$4.55	14K	72%	Form 4
Nov 21, 2024	John Alexander Kelly Chief Financial Officer	Bought	3,000	$6.76	20K	8.6%	Form 4

Sep 28
Stanley Frankel
Director · bought 1,000 at $6.00
6K
2.5% of stake
Sep 25
Melinda Brown
Director · bought 1,135 at $6.27
7K
2.6% of stake
Sep 25
Geno J Germano
Director · bought 2,609 at $6.28
16K
5.8% of stake
Feb 1810b5-1 plan
Michael Amoroso
President and CEO · sold 20,559 at $3.84
79K
7.8% of stake
Feb 1810b5-1 plan
John Alexander Kelly
Chief Financial Officer · sold 8,149 at $3.84
31K
6.1% of stake
Feb 1810b5-1 plan
Dario Scimeca
General Counsel and Secretary · sold 4,925 at $3.84
19K
8.0% of stake
Feb 1810b5-1 plan
J. Jefferson Smith
Chief Research Officer · sold 4,925 at $3.84
19K
3.7% of stake
Jan 2210b5-1 plan
Michael Amoroso
President and CEO · sold 34,799 at $4.17
145K
15% of stake
Jan 2110b5-1 plan
Dario Scimeca
General Counsel and Secretary · sold 8,854 at $4.03
36K
17% of stake
Jan 2110b5-1 plan
John Alexander Kelly
Chief Financial Officer · sold 15,213 at $4.03
61K
13% of stake
Jan 2110b5-1 plan
J. Jefferson Smith
Chief Research Officer · sold 10,200 at $4.03
41K
7.9% of stake
Dec 16, 2025
Geno J Germano
Director · bought 3,000 at $4.72
14K
14% of stake
Dec 16, 2025
Stanley Frankel
Director · bought 2,700 at $4.70
13K
16% of stake
Dec 15, 2025
Melinda Brown
Director · bought 1,381 at $4.97
7K
6.3% of stake
Nov 3, 202510b5-1 plan
John Alexander Kelly
Chief Financial Officer · sold 1,303 at $6.49
8K
1.7% of stake
Nov 3, 202510b5-1 plan
Dario Scimeca
General Counsel and Secretary · sold 665 at $6.49
4K
2.3% of stake
Nov 3, 202510b5-1 plan
Michael Amoroso
President and CEO · sold 3,409 at $6.49
22K
2.9% of stake
Sep 26, 2025
Stanley Frankel
Director · bought 2,700 at $4.97
13K
19% of stake
Sep 22, 2025
Melinda Brown
Director · bought 1,400 at $4.89
7K
6.8% of stake
Jul 3, 202510b5-1 plan
John Alexander Kelly
Chief Financial Officer · sold 14,827 at $4.26
63K
17% of stake
Jun 25, 2025
Melinda Brown
Director · bought 1,682 at $4.14
7K
8.9% of stake
Jun 25, 2025
Kevin Buehler
Director · bought 5,076 at $4.16
21K
22% of stake
Mar 26, 2025
Melinda Brown
Director · bought 1,839 at $4.75
9K
25% of stake
Mar 26, 2025
Kevin Buehler
Director · bought 4,523 at $4.67
21K
52% of stake
Mar 25, 2025
Geno J Germano
Director · bought 3,250 at $5.30
17K
42% of stake
Mar 24, 202510b5-1 plan
Michael Amoroso
President and CEO · sold 964 at $5.56
5K
0.9% of stake
Mar 4, 202510b5-1 plan
Dario Scimeca
General Counsel and Secretary · sold 272 at $4.91
1K
1.1% of stake
Mar 4, 202510b5-1 plan
J. Jefferson Smith
Chief Research Officer · sold 154 at $4.91
$756
0.2% of stake
Jan 22, 202510b5-1 plan
Dario Scimeca
General Counsel and Secretary · sold 8,928 at $4.79
43K
27% of stake
Jan 22, 202510b5-1 plan
J. Jefferson Smith
Chief Research Officer · sold 10,287 at $4.79
49K
9.7% of stake
Jan 21, 202510b5-1 plan
Michael Amoroso
President and CEO · sold 36,838 at $4.67
172K
26% of stake
Dec 30, 2024
Geno J Germano
Director · bought 3,605 at $4.49
16K
86% of stake
Dec 27, 2024
Kevin Buehler
Director · bought 4,320 at $4.88
21K
98% of stake
Dec 27, 2024
John Alexander Kelly
Chief Financial Officer · bought 2,113 at $4.75
10K
5.5% of stake
Dec 26, 2024
Melinda Brown
Director · bought 3,016 at $4.55
14K
72% of stake
Nov 21, 2024
John Alexander Kelly
Chief Financial Officer · bought 3,000 at $6.76
20K
8.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DTIL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with DTIL

CompareIntrinsic value

STROSutro Biopharma, Inc.

$9.94+4.52%10

PTHSPelthos Therapeutics Inc.

$10.15-5.84%0

EDITEditas Medicine Inc.

$2.73+5.00%40

CHRSCoherus Biosciences Inc.

$0.85+5.46%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

VYGRVoyager Therapeutics Inc.

$1.87+2.19%10

IVVDInvivyd Inc.

$0.63+8.93%10

Held by ETFs

DTIL is in 1 US ETF. The largest of them, with DTIL's weight in each:

iShares Micro-Cap ETFIWC0.04%of the fund

Spot a number that looks wrong? Check it in DTIL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DTIL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.